Cargando…
H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression
Background and Purpose: Septic cardiomyopathy, which is one of the features of multi-organ dysfunction in sepsis, is characterized by ventricular dilatation, reduced ventricular contractility, and reduction in ejection fraction and, if severe, can lead to death. To date, there is no specific therapy...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694767/ https://www.ncbi.nlm.nih.gov/pubmed/31440160 http://dx.doi.org/10.3389/fphar.2019.00865 |
_version_ | 1783443897273286656 |
---|---|
author | Tan, Sihua Long, Zhiyuan Hou, Xiangping Lin, Yujie Xu, Jingting You, Xinchao Wang, Tinghuai Zhang, Yaxing |
author_facet | Tan, Sihua Long, Zhiyuan Hou, Xiangping Lin, Yujie Xu, Jingting You, Xinchao Wang, Tinghuai Zhang, Yaxing |
author_sort | Tan, Sihua |
collection | PubMed |
description | Background and Purpose: Septic cardiomyopathy, which is one of the features of multi-organ dysfunction in sepsis, is characterized by ventricular dilatation, reduced ventricular contractility, and reduction in ejection fraction and, if severe, can lead to death. To date, there is no specific therapy that exists, and its treatment represents a large unmet clinical need. Herein, we investigated the effects and underlying anti-inflammatory mechanisms of hydrogen gas in the setting of lipopolysaccharide (LPS)-induced cardiomyocytes injury. Experimental Approach: Hydrogen gas was intraperitoneally injected to mice in LPS plus hydrogen group and hydrogen group for 4 days. On fourth, LPS was given by intraperitoneal injection to mice in LPS group and to mice in LPS plus hydrogen group. In addition, H9c2 cardiomyocytes were treated with hydrogen-rich medium for 30 min before LPS. The transthoracic echocardiography was performed at 6 h post‐LPS to assess left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (EF%), fractional shortening (FS%), left ventricular mass average weight (LV mass AW), and LV mass AW (Corrected). The histological and morphological analyses of left ventricular were performed by hematoxylin and eosin (H&E) staining and Masson’s trichrome staining. The mRNA levels of ANP and BNP were examined by PCR in vitro. The expression of cytokines were assayed by Enzyme Linked Immunosorbent Assay (ELISA) and PCR. Moreover, Western blotting was performed to examine the expression of TLR4, the activation of ERK1/2, p38, JNK, and the expression of NF-κB in nucleus after 6 h of LPS challenge in vivo and in vitro. Key Results: LPS induced cardiac dysfunction; hydrogen therapy improved cardiac function after LPS challenge. Furthermore, pretreatment with hydrogen resulted in cardioprotection during septic cardiomyopathy via inhibiting the expression of pro-inflammatory cytokines TNFα, IL-1β, and IL-18; suppressing the phosphorylation of ERK1/2, p38, and JNK; and reducing the nuclear translocation of NF-κB and the expression of TLR4 by LPS. Conclusion and Implications: Hydrogen therapy prevents LPS-induced cardiac dysfunction in part via downregulation of TLR4-mediated pro-inflammatory cytokines expression. |
format | Online Article Text |
id | pubmed-6694767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66947672019-08-22 H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression Tan, Sihua Long, Zhiyuan Hou, Xiangping Lin, Yujie Xu, Jingting You, Xinchao Wang, Tinghuai Zhang, Yaxing Front Pharmacol Pharmacology Background and Purpose: Septic cardiomyopathy, which is one of the features of multi-organ dysfunction in sepsis, is characterized by ventricular dilatation, reduced ventricular contractility, and reduction in ejection fraction and, if severe, can lead to death. To date, there is no specific therapy that exists, and its treatment represents a large unmet clinical need. Herein, we investigated the effects and underlying anti-inflammatory mechanisms of hydrogen gas in the setting of lipopolysaccharide (LPS)-induced cardiomyocytes injury. Experimental Approach: Hydrogen gas was intraperitoneally injected to mice in LPS plus hydrogen group and hydrogen group for 4 days. On fourth, LPS was given by intraperitoneal injection to mice in LPS group and to mice in LPS plus hydrogen group. In addition, H9c2 cardiomyocytes were treated with hydrogen-rich medium for 30 min before LPS. The transthoracic echocardiography was performed at 6 h post‐LPS to assess left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (EF%), fractional shortening (FS%), left ventricular mass average weight (LV mass AW), and LV mass AW (Corrected). The histological and morphological analyses of left ventricular were performed by hematoxylin and eosin (H&E) staining and Masson’s trichrome staining. The mRNA levels of ANP and BNP were examined by PCR in vitro. The expression of cytokines were assayed by Enzyme Linked Immunosorbent Assay (ELISA) and PCR. Moreover, Western blotting was performed to examine the expression of TLR4, the activation of ERK1/2, p38, JNK, and the expression of NF-κB in nucleus after 6 h of LPS challenge in vivo and in vitro. Key Results: LPS induced cardiac dysfunction; hydrogen therapy improved cardiac function after LPS challenge. Furthermore, pretreatment with hydrogen resulted in cardioprotection during septic cardiomyopathy via inhibiting the expression of pro-inflammatory cytokines TNFα, IL-1β, and IL-18; suppressing the phosphorylation of ERK1/2, p38, and JNK; and reducing the nuclear translocation of NF-κB and the expression of TLR4 by LPS. Conclusion and Implications: Hydrogen therapy prevents LPS-induced cardiac dysfunction in part via downregulation of TLR4-mediated pro-inflammatory cytokines expression. Frontiers Media S.A. 2019-08-05 /pmc/articles/PMC6694767/ /pubmed/31440160 http://dx.doi.org/10.3389/fphar.2019.00865 Text en Copyright © 2019 Tan, Long, Hou, Lin, Xu, You, Wang and Zhang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Tan, Sihua Long, Zhiyuan Hou, Xiangping Lin, Yujie Xu, Jingting You, Xinchao Wang, Tinghuai Zhang, Yaxing H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression |
title | H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression |
title_full | H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression |
title_fullStr | H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression |
title_full_unstemmed | H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression |
title_short | H(2) Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression |
title_sort | h(2) protects against lipopolysaccharide-induced cardiac dysfunction via blocking tlr4-mediated cytokines expression |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694767/ https://www.ncbi.nlm.nih.gov/pubmed/31440160 http://dx.doi.org/10.3389/fphar.2019.00865 |
work_keys_str_mv | AT tansihua h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression AT longzhiyuan h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression AT houxiangping h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression AT linyujie h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression AT xujingting h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression AT youxinchao h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression AT wangtinghuai h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression AT zhangyaxing h2protectsagainstlipopolysaccharideinducedcardiacdysfunctionviablockingtlr4mediatedcytokinesexpression |